Treosulfan Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 1 g, 5 g
Reference Brands: Trecondi (EU/UK)
Category:
Oncology Cancer Care
Treosulfan is available in Injection
and strengths such as 1 g, 5 g.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Treosulfan is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Treosulfan can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Treosulfan is an alkylating antineoplastic agent used as part of conditioning regimens prior to allogeneic hematopoietic stem cell transplantation (HSCT). It is administered to patients before bone marrow transplantation to eliminate existing bone marrow cells and create space for donor stem cells to engraft and produce healthy blood cells. Treosulfan is commonly marketed under the brand name Trecondi in regulated markets.
Treosulfan is used in combination with fludarabine in both adult and pediatric patients, including children from one month of age, for the treatment of hematological malignancies such as blood cancers, as well as in adults with certain severe non-malignant disorders that require stem cell transplantation. It belongs to the class of alkylating agents and exerts its therapeutic effect through cytotoxic activity on rapidly dividing cells.
After administration, treosulfan is converted in the body into active epoxide compounds. These metabolites bind to cellular DNA during cell division, causing DNA damage and leading to cell death, particularly in rapidly proliferating tissues such as bone marrow. Due to its predictable pharmacokinetics and controlled toxicity profile, treosulfan plays an important role in modern transplant conditioning protocols under specialist medical supervision.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing